Pain Management

Studies Assess Lasmiditan’s Safety in Pediatric and Elderly Migraine Patients

October 16th 2020, 9:00pm


Two abstracts presented at the Migraine Trust Virtual Symposium investigated lasmiditan’s safety in elderly and pediatric migraine patients.

Research Outlines Safety, Tolerability of Lasmiditan for Migraine

October 5th 2020, 4:57pm


Abstracts presented at this year’s Migraine Trust International Symposium (MTIS) show how researchers analyzed the efficacy, tolerability, and safety profile of Reyvow (lasmiditan), a prescription drug used to treat migraine attacks.

Research Examines Chronic Pain Relationships in Patient-Reported Outcomes

October 3rd 2020, 8:00pm


Understanding and targeting all factors involved in chronic pain can improve the success of treatments.

Study Examines Impact of Orofacial Pain Characteristics

October 3rd 2020, 5:30pm


The characteristics and degree of psychosocial morbidity in patients with orofacial pain is significantly related to the types of presenting orofacial symptoms.

No Ill Effects for Older Adults Using Medical Cannabis for Pain, Study Says

September 26th 2020, 9:00pm


A study looking at older adults with chronic pain found no significant difference in cognitive performance when comparing them with matched patients who did not use medical cannabis.

Trial Results Show Pain Relief Benefit of Lasmiditan 2 Hours After Migraine Attack

September 25th 2020, 6:30pm


Patients with migraine who took lasmiditan (Reyvow) for acute pain during attacks had greater odds of reaching pain freedom, according to results of a phase 3 trial.

Multidisciplinary Pain Care Difficult to Access, Report Says

September 19th 2020, 7:45pm


The survey was released to mark Pain Awareness Month.

Pain 1 of 3 in a Cluster of Symptoms Affecting Men After Prostate Cancer

September 12th 2020, 8:45pm


Pain, fatigue, and depression are 1 cluster of symptoms afflicting 1 in 13 survivors of prostate cancer, according to a recent study.

Phase 3 Migraine Trial of DHE in Nasal Form Fails to Show Significant Difference

September 10th 2020, 11:15pm


A formulation of dihydroergotamine (DHE) in a nasal powder form was no different than placebo for relief from pain and annoying symptoms at 2 hours post dose.

Study Examines Cardiovascular Effects of Lasmiditan, Propranolol

September 5th 2020, 4:00am


In clinical practice, lasmiditan may be given together with propranolol; investigators wanted to test the cardiovascular effects of coadministration.